Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Pharmaceuticals-&-Medical-Devices-Bureau-of-India"

5 News Found

New products and nutraceuticals added under Jan Aushadhi Pariyojana
Policy | July 31, 2023

New products and nutraceuticals added under Jan Aushadhi Pariyojana

The product basket increased to 1800 medicines and 285 Surgical Equipment

Department of Pharmaceuticals to celebrate 5th Jan Aushadhi Diwas on March 7
News | March 01, 2023

Department of Pharmaceuticals to celebrate 5th Jan Aushadhi Diwas on March 7

Jan Aushadhi Diwas celebrations to generate awareness about the usages of generic medicines and benefits of Jan Aushadhi Pariyojana

PMBI launches Jan Aushadhi Chyawanprash Special
News | January 06, 2023

PMBI launches Jan Aushadhi Chyawanprash Special

Chyawanprash Special will be available at all Jan Aushadhi Kendras

Affordable Sitagliptin combinations for diabetics to be sold at Janaushadhi Kendras
Healthcare | September 19, 2022

Affordable Sitagliptin combinations for diabetics to be sold at Janaushadhi Kendras

Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

PMBI first time ever crossed Rs. 100 crore sales in May, 2022
Policy | June 02, 2022

PMBI first time ever crossed Rs. 100 crore sales in May, 2022

Govt. has set a target to increase the number of JanAushadhi Kendras to 10,000 by March 2024

Latest Stories

CHMP adopts positive opinion recommending approval of Bristol Myers Squibb’s Opdivo in combination with Cisplatin and Gemcitabine

AstraZeneca 1Q 2024 revenue up 19% to US$ 12,679 million

Takeda receives positive CHMP opinion for Fruquintinib in previously treated mCRC

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries
We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region
We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region
Vinod Paremal President & MD, Evonik, India Region

Packaging